TY - JOUR
T1 - Differential Survival characteristics of sarcomatoid subtype biphasic pleural mesothelioma
AU - Harling, Leanne
AU - Kolokotroni, Styliani Maria
AU - Nair, Arjun
AU - Smelt, Jeremy
AU - King, Juliet
AU - Routledge, Tom
AU - Spicer, James
AU - Ng, Wen
AU - Bille, Andrea
PY - 2018/10/30
Y1 - 2018/10/30
N2 - Background Biphasic mesothelioma (BPM) accounts for approximately 10% of all pleural mesothelioma. Our aim was to assess the clinical, radiological and pathological factors impacting survival in BPM and to better identify patients most likely to benefit from active treatment. Methods Ten-year retrospective review of 214 biopsy-proven BPM cases with minimum 2-year follow-up. Patients with insufficient tissue for analysis were excluded (n=96). Clinical and pathological factors were evaluated along with radiological assessment of pleural thickness. Survival was measured from time of diagnosis. Uni- and multi-variable predictors of survival were evaluated. Results 118 patients were included. 28 underwent pleurectomy/decortication (P/D), with 27 receiving additional modalities. 90 underwent chemotherapy (n=18) or radiotherapy alone (n=9), 63 received combination therapy, and 27 received best supportive care (BSC). Median overall survival was 11.2 months (0.3–36.2). At univariable analysis, P/D (p=0.0061), radiotherapy (RT; p
AB - Background Biphasic mesothelioma (BPM) accounts for approximately 10% of all pleural mesothelioma. Our aim was to assess the clinical, radiological and pathological factors impacting survival in BPM and to better identify patients most likely to benefit from active treatment. Methods Ten-year retrospective review of 214 biopsy-proven BPM cases with minimum 2-year follow-up. Patients with insufficient tissue for analysis were excluded (n=96). Clinical and pathological factors were evaluated along with radiological assessment of pleural thickness. Survival was measured from time of diagnosis. Uni- and multi-variable predictors of survival were evaluated. Results 118 patients were included. 28 underwent pleurectomy/decortication (P/D), with 27 receiving additional modalities. 90 underwent chemotherapy (n=18) or radiotherapy alone (n=9), 63 received combination therapy, and 27 received best supportive care (BSC). Median overall survival was 11.2 months (0.3–36.2). At univariable analysis, P/D (p=0.0061), radiotherapy (RT; p
KW - Biphasic Mesothelioma
KW - Histopathology
KW - Survival
KW - Pleurectomy/decortication
KW - radiotherapy
U2 - 10.1016/j.athoracsur.2018.09.019
DO - 10.1016/j.athoracsur.2018.09.019
M3 - Article
SN - 0003-4975
JO - Annals of Thoracic Surgery
JF - Annals of Thoracic Surgery
ER -